Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy

Inhibitory antibodies to factor VIII (FVIII) are a major complication in the treatment of hemophilia A, affecting approximately 20% to 30% of patients. Current treatment for inhibitors is based on long-term, daily injections of large amounts of FVIII protein. Liver-directed gene therapy has been use...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Finn, Jonathan D., Ozelo, Margareth C., Sabatino, Denise E., Franck, Helen W. G., Merricks, Elizabeth P., Crudele, Julie M., Zhou, Shangzhen, Kazazian, Haig H., Lillicrap, David, Nichols, Timothy C., Arruda, Valder R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2010
Assuntos:
Gene Therapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3031380/
https://ncbi.nlm.nih.gov/pubmed/20876851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-06-288001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados